Model 1 | Model 2 | Model 3 | |
---|---|---|---|
RR (95% CI) | RR (95% CI) | RR (95% CI) | |
Panel 1: Gonorrhoea | |||
Convenience vendors | 0.33 (0.27 to 0.40) | 0.73 (0.60 to 0.89) | 0.75 (0.61 to 0.92) |
Concentrated disadvantage | – | 2.01 (1.93 to 2.10) | 2.01 (1.92 to 2.09) |
Free locations | – | – | 1.24 (0.91 to 1.71) |
Panel 2: Chlamydia | |||
Convenience vendors | 0.24 (0.17 to 0.32) | 0.56 (0.43 to 0.83) | 0.60 (0.43 to 0.83) |
Concentrated disadvantage | – | 2.09 (1.96 to 2.24) | 2.09 (1.96 to 2.23) |
Free locations | – | – | 1.42 (0.90 to 2.25) |
Panel 2: HIV | |||
Convenience vendors | 0.59 (0.40 to 0.87) | 0.67 (0.45 to 0.99) | 1.04 (0.66 to 1.63) |
Concentrated disadvantage | – | 1.15 (1.06 to 1.26) | 1.16 (1.06 to 1.27) |
Free locations | – | – | 3.52 (1.84 to 6.81) |
Model 1 included convenience vendors.
Model 2 included convenience vendors and concentrated disadvantage.
Model 3 included convenience vendors, concentrated disadvantage and free condom locations.